Clinical Trials Browser

Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Rombo syndrome, Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Syndrome, Xeroderma Pigmentosum

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Medulloblastoma

Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Neoplasms

Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Skin Neoplasms

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Skin Neoplasms

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Neoplasms

Basal Cell Nevus Syndrome, Colonic Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Basal cell carcinoma, multiple, Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Clinical Trials

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

GDC-0449

Vismodegib

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

BCC

ASN-002-001

Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants

SIGNATURE

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

NPEF

Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.